RMD | Jotup

ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference

Retrieved on:

Tuesday, September 6, 2022

RMD, Conditional sentence, Quality of life, ASX, Sheraton New York Times Square Hotel, Caregiver, NYSE, Sleep apnea, GLOBE, ResMed, Conference, SAN, COPD, Health insurance

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. (Eastern Daylight Time) at the Sheraton New York in New York City.

Key Points:

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. (Eastern Daylight Time) at the Sheraton New York in New York City.
More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .
The webcast replay will be available approximately 3 hours after the live webcast ends and will be accessible through March 11, 2023.
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.

Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

Retrieved on:

Sunday, September 4, 2022

Advanced stages may require supplemental oxygen or mechanical ventilation in the home or hospital.

Key Points:

Advanced stages may require supplemental oxygen or mechanical ventilation in the home or hospital.
Researchers expect that number to reach an estimated 592 million by 2050 if current risk factor trends continue.
This number should be a warning, said study co-author and ResMed Chief Medical Officer Carlos M. Nunez, M.D.
Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.

US Army awards Raytheon Missiles & Defense $182 million NASAMS contract for Ukraine

Retrieved on:

Friday, August 26, 2022

Sentinel, RMD, Raytheon Technologies, Raytheon Missiles & Defense, NYSE, Raytheon Intelligence & Space, NASAMS, Physics, Solution, Kongsberg Defence Systems, Raytheon Company, Aircraft, National Advanced Driving Simulator, United Technologies, Defense, KDA, Pratt & Whitney, Weapon

"Raytheon Missiles & Defense and our partners are working diligently to quickly deliver this critical, proven air defense capability to help the Ukrainian people defend their homeland," said Tom Laliberty, president of Land Warfare & Air Defense, a Raytheon Missiles & Defense business area.

Key Points:

"Raytheon Missiles & Defense and our partners are working diligently to quickly deliver this critical, proven air defense capability to help the Ukrainian people defend their homeland," said Tom Laliberty, president of Land Warfare & Air Defense, a Raytheon Missiles & Defense business area.
"Ukraine will join a dozen nations around the globe who rely on NASAMS to defeat a multitude of threats, including cruise missiles, aircraft, and unmanned systems."
Raytheon Technologies Corporation is an aerospace and defense company that provides advanced systems and services for commercial, military and government customers worldwide.
With four industry-leading businesses Collins Aerospace, Pratt & Whitney, Raytheon Intelligence & Space and Raytheon Missiles & Defense the company delivers solutions that push the boundaries in avionics, cybersecurity, directed energy, electric propulsion, hypersonics, and quantum physics.

RMD Advertising Becomes Agency of Record for Decadent, Plant-Based Dessert Brand

Retrieved on:

Saturday, August 6, 2022

Cream, Public relations, Pleasure, Partner (business rank), The Non-GMO Project, Ice cream, Knowledge, Problem solving, Advertising, Rest, Guilt, Amazon Fresh, Awareness, Social media, Solution, RMD, J. R. O'Dwyer Company, Department store, Sales

COLUMBUS, Ohio, Aug. 5, 2022 /PRNewswire-PRWeb/ -- RMD Advertising, a fully integrated advertising, public relations, social media and brand strategy agency, focusing exclusively on growing challenger food and beverage brands, announces the addition of Bon Dévil to its roster of established, blue chip food clients. Beginning Summer, 2022, RMD will help to bring increased brand awareness and to the ever-growing retail footprint of the brand. Bon Dévil, known for its gloriously delectable, plant-based ganache, will lean on RMD's integrated agency strategies and expertise to help grow the brand, its footprint and consumer love

Key Points:

Bon Dvil Looks to Recognized Challenger Food Agency, RMD Advertising, For Integrated Brand Expertise
COLUMBUS, Ohio, Aug. 5, 2022 /PRNewswire-PRWeb/ -- RMD Advertising, a fully integrated advertising, public relations, social media and brand strategy agency, focusing exclusively on growing challenger food and beverage brands, announces the addition of Bon Dvil to its roster of established, blue chip food clients.
Beginning Summer, 2022, RMD will help to bring increased brand awareness and to the ever-growing retail footprint of the brand.
"We've been in love with this brand for quite awhile.
It's perfect for today's consumer, checks so many of the most important boxes, and above all has a flavor that is absolutely unbeatable," shares Sue Reninger, Managing Partner and Client Brand Strategist for RMD Advertising.

ResMed Acquires Leipzig-based mementor with Insomnia Digital Health Solution somnio

Retrieved on:

Tuesday, August 2, 2022

With this acquisition, ResMed strengthens its overall sleep portfolio in Germany with a digital solution for insomnia.

Key Points:

With this acquisition, ResMed strengthens its overall sleep portfolio in Germany with a digital solution for insomnia.
Founded in 2014 and based in Leipzig, Germany, mementor developed and owns the digital insomnia therapy solution somnio, which is Germanys first and only permanently approved Digital Health Application (DiGA) in the field of sleep medicine and thus eligible for reimbursement in Germany.
Through the acquisition, mementor can leverage ResMed Germanys broader network to increase adoption of its approved digital therapy alternative for insomnia; somnio is available today in Germany via app on prescription.
With somnio, mementor operates the first and so far only digital health application (DiGA) for the treatment of insomnia.

Liberty Global Selects CommScope as DOCSIS 4.0 Technology Partner

Retrieved on:

Tuesday, July 19, 2022

CommScope (NASDAQ: COMM) announced today that it was selected by Liberty Global to develop and deploy a Remote MACPHY Device (RMD) Node platform for DOCSIS 4.0 (D4.0), accelerating Liberty Globals progress towards 10G capabilities.

Key Points:

CommScope (NASDAQ: COMM) announced today that it was selected by Liberty Global to develop and deploy a Remote MACPHY Device (RMD) Node platform for DOCSIS 4.0 (D4.0), accelerating Liberty Globals progress towards 10G capabilities.
View the full release here: https://www.businesswire.com/news/home/20220719005204/en/
Liberty Global Selects CommScope as DOCSIS 4.0 Technology Partner (Photo: Business Wire)
This project marks the industrys first D4.0 initiative in Europe and leverages CommScopes DOCSIS leadership and end-to-end portfolio of solutions to deliver a new custom node and RMD platform specifically for Liberty Global.
Our groundbreaking D4.0 project is an important step forward in our 10G vision for the future, stated Colin Buechner, Managing Director and Chief Network Officer, Liberty Global.
We are excited to partner with Liberty Global once again as we demonstrate our worldwide leadership in DOCSIS, said Guy Sucharczuk, SVP and President, Access Network Solutions, CommScope.

ResMed to Report Fourth Quarter Fiscal 2022 Earnings on August 11, 2022

Retrieved on:

Thursday, July 14, 2022

Sleep apnea, Quality of life, COPD, Conditional sentence, Caregiver, NYSE, ResMed, ASX, RMD, Webcast, Health insurance

Please note that ResMed does not use outside phone lines to access the earnings call.

Key Points:

Please note that ResMed does not use outside phone lines to access the earnings call.
A replay of the earnings webcast will be accessible on ResMeds website and available approximately two hours after the webcast.
Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.
Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.

ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care

Retrieved on:

Tuesday, June 28, 2022

A board member of MedTech Europe since 2020; President of the Snitem, Frances premier medtech association

Key Points:

A board member of MedTech Europe since 2020; President of the Snitem, Frances premier medtech association
SAN DIEGO, June 28, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022.
Blaise, currently ResMeds Vice President of Sleep & Respiratory Care for Western Europe, is a medtech industry thought leader with over 25 years experience in medical device sales, marketing, finance, and business development.
Im thrilled that Lucile one of Europes leading champions of digital health innovation and adoption, as well as data privacy and security has accepted this promotion to lead ResMeds global Sleep & Respiratory Care business, said ResMed CEO Mick Farrell.
Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.

Trendsetter In Meme DAO Governance RemeDAO Four Great Features In One Rebase Meme Token DAO And Anti Whale Dump

Retrieved on:

Monday, June 20, 2022

Crypto, Time, Chart, Attention, SHIB, RMD, Crash, Meme, Research, DAO, APY, Whale, GLOBE, Sale, Cryptocurrency

We want to be rich and win in this market, but still dont know where to find the best solution.

Key Points:

We want to be rich and win in this market, but still dont know where to find the best solution.
and REMEDAO got all you want, REMEDAO is the next generation of HOLD to EARN Model, a combination of 3 awesome things in Crypto World: Rebase system, Meme token, DAO.
REMEDAO has a great anti whale dump system, along with a sustainable APY rate of 368,296.57%.
Im afraid not, besides owning the ultimate anti whale dump system, the lower people sell coins, the more healthy the chart is.

ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions

Retrieved on:

Tuesday, June 14, 2022

With the acquisition of MEDIFOX DAN, a fast-growing and innovative German healthcare software leader, we will expand ResMeds SaaS business portfolio outside our current base in the U.S. market and strengthen our position as the global leader in healthcare software solutions for lower-cost and lower-acuity care, said Mick Farrell, ResMed CEO.

Key Points:

With the acquisition of MEDIFOX DAN, a fast-growing and innovative German healthcare software leader, we will expand ResMeds SaaS business portfolio outside our current base in the U.S. market and strengthen our position as the global leader in healthcare software solutions for lower-cost and lower-acuity care, said Mick Farrell, ResMed CEO.
MEDIFOX DAN has a strong track record of innovation, fully aligned with our teams at Brightree, MatrixCare, and beyond.
ResMed plans for MEDIFOX DAN to operate under its current brand within the ResMed SaaS business as Brightree and MatrixCare do today.
Under the agreement terms, ResMed will acquire MEDIFOX DAN for approximately US$1.0 billion (950 million), which ResMed expects to fund with its existing credit facilities.